Focus Partners Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$22.3M Buy
29,358
+15,315
+109% +$11.6M 0.02% 486
2026
Q2
$8.76M Sell
14,043
-2,398
-15% -$1.63M 0.01% 757
2026
Q1
$12.7M Buy
16,441
+4,535
+38% +$3.47M 0.01% 640
2025
Q4
$9.19M Buy
11,906
+2,754
+30% +$1.87M 0.01% 728
2025
Q3
$5.15M Buy
9,152
+3,785
+71% +$2.14M 0.01% 735
2025
Q2
$2.82M Sell
5,367
-579
-10% -$323K 0.01% 813
2025
Q1
$3.77M Sell
5,946
-3,280
-36% -$2.26M 0.01% 707
2024
Q4
$6.57M Buy
9,226
+6,255
+211% +$5.25M 0.02% 552
2024
Q3
$3.12M Sell
2,971
-3,922
-57% -$4.36M 0.01% 673
2024
Q2
$7.24M Buy
6,893
+1,900
+38% +$1.84M 0.02% 428
2024
Q1
$4.81M Buy
4,993
+2,319
+87% +$2.21M 0.04% 328
2023
Q4
$2.35M Buy
+2,674
New +$2.2M 0.03% 328

Other funds holding REGN

Focus Partners Wealth's REGN Position: Q3 2026 in Review

Focus Partners Wealth increased its Regeneron Pharmaceuticals (REGN) stake by 109% in Q3 2026, buying an estimated $11.6M and bringing the position to 29,358 shares worth $22.3M. The position accounts for 0.02% of the portfolio, ranked #486.

Focus Partners Wealth first reported a position in REGN in Q4 2023 and has held it in 12 quarters since. 1,423 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Focus Partners Wealth held 29,358 shares of Regeneron Pharmaceuticals worth $22.3M as of Q3 2026.
  • Focus Partners Wealth bought 15,315 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $11.6M.
  • Regeneron Pharmaceuticals made up 0.02% of Focus Partners Wealth's portfolio in Q3 2026, its #486 holding.
  • Focus Partners Wealth first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 12 quarters since.
  • 1,423 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Focus Partners Wealth's 13F filing for Q3 2026, filed 12 Nov 2026.